Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

34.1K
Overview
34.1K
Vaccines01:21

Vaccines

62
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
62
Vaccinations01:51

Vaccinations

54.7K
Overview
54.7K
Cancer Vaccines01:30

Cancer Vaccines

1.4K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transgene Expression Kinetics and Replication Potential of Recombinant Adenovirus Serotype 4 in a Mouse Model and its Use as a Herpes Simplex Virus Vaccine.

bioRxiv : the preprint server for biology·2026
Same author

Immunization with Herpes Simplex Virus Nanoparticles Targeting Both Attachment and Fusion Protect Against Infection.

bioRxiv : the preprint server for biology·2026
Same author

Intranasal Replicating Adenovirus type 4-SARS-CoV-2 Recombinants Induce Superior Immune Response Durability and Efficacy in Preclinical Testing Compared to Standard Intramuscular Vaccines.

bioRxiv : the preprint server for biology·2026
Same author

Intranasal replicating adenovirus type 4-vectored SARS-CoV-2 vaccines induce durable and efficacious responses in preclinical testing.

iScience·2026
Same author

Enhancing, controlling, and sterilizing dengue immunity and the development of broadly protective responses.

medRxiv : the preprint server for health sciences·2026
Same author

Targeted deep sequencing identifies mosaicism in patients with immune dysregulation.

The Journal of allergy and clinical immunology·2026
Same journal

Safety and immunogenicity of an adjuvanted human onchocerciasis vaccine candidate, <i>Ov</i>MANE1: preclinical evaluation in a mice model.

Clinical & translational immunology·2026
Same journal

Early brain-penetrant immunotherapy reverses interferon signature and improves motor outcome in a case of ADAR1-related Aicardi-Goutières syndrome.

Clinical & translational immunology·2026
Same journal

Clinical, biological and cytometric characteristics of two patients with a homozygous A91V<i>PRF1</i> mutation.

Clinical & translational immunology·2026
Same journal

Effect of CXCR5, PD-1 and ICOS on B-cell responses and relevance to myasthenia gravis.

Clinical & translational immunology·2026
Same journal

Development and functional adaptation of intestinal macrophages across the lifespan.

Clinical & translational immunology·2026
Same journal

Myeloid HDAC7 drives liver inflammation and systemic glucose dysregulation during diet-induced obesity.

Clinical & translational immunology·2026
See all related articles

Related Experiment Video

Updated: Apr 17, 2026

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

4.8K

Epstein-barr virus vaccines.

Jeffrey I Cohen1

  • 1Medical Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MD, USA.

Clinical & Translational Immunology
|February 12, 2015
PubMed
Summary
This summary is machine-generated.

Developing an Epstein-Barr virus (EBV) vaccine is crucial for preventing infectious mononucleosis and associated cancers. Current vaccine strategies show promise but require further development for widespread efficacy against EBV-related diseases.

More Related Videos

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.9K
Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

41.5K

Related Experiment Videos

Last Updated: Apr 17, 2026

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

4.8K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.9K
Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

41.5K

Area of Science:

  • Virology
  • Immunology
  • Oncology

Background:

  • Epstein-Barr virus (EBV) causes infectious mononucleosis and is linked to various epithelial and lymphoid malignancies.
  • Currently, no licensed vaccines exist for primary EBV infection or EBV-associated cancers.
  • Significant global burden of nearly 200,000 new EBV-associated malignancies annually underscores the need for effective vaccines.

Purpose of the Study:

  • To review the current landscape of EBV vaccine development.
  • To highlight the potential of therapeutic vaccines for EBV-associated malignancies based on T-cell infusion successes.
  • To emphasize the urgent need for licensed EBV vaccines.

Main Methods:

  • Review of existing prophylactic vaccine strategies, primarily targeting EBV gp350.
  • Analysis of therapeutic vaccine approaches targeting EBV LMP2 and EBV nuclear antigen-1.
  • Consideration of T-cell therapy as a proof of principle for therapeutic vaccination.

Main Results:

  • A phase 2 trial of an EBV gp350 vaccine demonstrated a reduction in infectious mononucleosis but not viral infection.
  • Infusion of EBV-specific T cells shows promise in reducing EBV-associated malignancies like Hodgkin lymphoma and nasopharyngeal carcinoma.
  • Existing vaccine research has primarily focused on gp350 for prophylactic use and LMP2/EBNA-1 for therapeutic applications.

Conclusions:

  • While prophylactic EBV gp350 vaccines have shown partial success, further development is needed.
  • T-cell-based immunotherapy provides a strong rationale for developing therapeutic EBV vaccines.
  • An effective EBV vaccine is urgently required to combat the substantial global burden of EBV-associated cancers.